
Annex to the Report of the Coordinating Group

45th Board Meeting

GF/B45/10_Annex

11-12 May 2021, *Virtual*

Board Information

Annex 1 to GF/B45/10, providing overview of decisions taken by the three committees between the 44th and 45th Board Meetings.

Annex 1 to GF/B45/10:

Committee Decisions adopted between the 44th and 45th Board meetings
(12 November 2020 – 11 May 2021)

Decision Points approved by the Ethics and Governance Committee between the 44th and 45th Board Meetings	
DP Ref. No.	Title
15th EGC Meeting, 23-24 March 2021	
No decisions taken	

Decision Points approved by the Strategy Committee between the 44th and 45th Board Meetings	
DP Ref. No.	Title
14th SC Meeting	
GF/SC14/EDP01	Independent Evaluation Strategic Initiative: Technical Evaluation Reference Group Investment Plan (Phase 1)
15th SC Meeting	
GF/SC15/DP01	Second Extension of the Timeline for Including COVID-19 Products in the wambo.org Pilot
GF/SC15/DP02	KPI Adjustments

14th Strategy Committee Meeting Decision Points

Points

GF/SC14/EDP01: Independent Evaluation Strategic Initiative

Technical Evaluation Reference Group Investment Plan (Phase 1)

1. The Strategy Committee (the “SC”) approves the use of a maximum amount of USD 5.5 million from the funds set aside for the TERG Independent Evaluation Strategic Initiative (GF/B41/DP04) to implement the activities described in Phase 1 of the Technical Evaluation Reference Group (the “TERG”)’s Investment Case Proposal, as presented in GF/SC14/ER01.
2. The TERG will present a final investment case proposal for the use of the remaining funds from the TERG Independent Evaluation Strategic Initiative to the SC for approval before the end of 2021 taking into account the anticipated discussions around monitoring and evaluation, including the independent evaluation function, in the Global Fund, as well as any other input provided by the SC.

Budgetary implications (included in, or additional to, OPEX budget): none

15th Strategy Committee Meeting Decision Points

Points

GF/SC15/DP01: Second Extension of the Timeline for Including COVID-19 Products in the wambo.org Pilot

1. The Strategy Committee (“SC”):
 - a. Recalls GF/B43/EDP07 where the Board (i) decided to extend the scope of the wambo.org pilot to allow for eligible buyers, as defined in GF/B42/DP05, to purchase all COVID-19 products available in wambo.org for procurement by Global Fund Principal Recipients and (ii) specified that such non-Global Fund financed transactions for COVID-19 products will be issued as purchase orders by wambo.org within the period ending 31 December 2020, unless extended by the Board following recommendation by the SC;
 - b. Recalls GF/B43/EDP17 where the Board approved the change in the end date of such period to 31 May 2021;
 - c. Acknowledges its review and discussion of the proposal to change the period during which purchase orders for such non-Global Fund financed transactions for COVID-19 products may be issued until November 2022 or until the Board

- approves a future strategy for wambo.org, subject to the continued applicability of all other conditions and flexibilities set forth in GF/B43/EDP07; and
- d. Decides to recommend the change in the end date of the period in which these flexibilities may be used to facilitate broader access to COVID-19 products to November 2022 or until the Board approves a future strategy for wambo.org if earlier, to the Board for approval at its 45th meeting.

2. Accordingly, the SC recommends the following decision point to the Board for approval at its 45th meeting:

Decision Point: GF/B45/DPXX: Second Extension of the Timeline for Including COVID-19 Products in the wambo.org Pilot

The Board:

1. Recalls GF/B43/EDP07 where it decided to extend the scope of the wambo.org pilot to allow for eligible buyers, as defined in GF/B42/DP05, to purchase all COVID-19 products available in wambo.org for procurement by Global Fund Principal Recipients and specified that such non-Global Fund financed transactions for COVID-19 products will be issued as purchase orders by wambo.org within the period ending 31 December 2020, unless extended by the Board following recommendation by the Strategy Committee;
2. Recalls GF/B43/EDP17 where the Board approved the change in the end date of such period to 31 May 2021; and
3. Based on the recommendation of the Strategy Committee, approves the change in the end date of such period through which non-Global Fund financed transactions for COVID-19 products may be issued as purchase orders by wambo.org until November 2022 or until the Board approves a future strategy for wambo.org if earlier and confirms that all other conditions and flexibilities set forth in GF/B43/EDP07 shall continue to apply.

Budgetary implications (included in, or additional to, OPEX budget)

The cost of additional licenses associated with the use of wambo.org will be absorbed within the Secretariat's existing license packages, which currently include some unused licenses. If further licenses are needed, costs and options to cover these costs will be evaluated by the Secretariat.

Costs relating to the expansion of the product catalogue to include COVID-19 products, which are already being incurred as a result of the creation of C19RM under GF/B42/EDP11, will be managed within the existing budget and will be incurred independently of this decision.

There are no other anticipated budgetary implications at this time, as new buyer onboardings and transactions will be managed by existing staff.

GF/SC15/DP02: KPI Adjustments

1. Based on its review and discussion of the proposals presented by the Secretariat, the Strategy Committee (the "SC") recommends that the Board approve revisions to Key Performance Indicators 2, 5c, 6e, 9c and 11 as set forth in GF/SC15/DPXX.
2. Accordingly, the SC recommends the following decision point to the Board for approval at its 45th Meeting in May 2021:

GF/B45/EDPXX: KPI Adjustments

Based on the recommendation of the Strategy Committee, the Board approves the revisions to Key Performance Indicators 2, 5c, 6e, 9c and 11 as presented in GF/B45/ERXX.

This decision has no budgetary implications.

Decision Points approved by the Audit and Finance Committee between the 44th and 45th Board Meetings	
DP Ref. No.	Title
14th AFC Meeting	
GF/AFC14/EDP03	Amendments to Provident Fund Constitutional Declaration and Benefits Rules
GF/AFC14/EDP04	Approval of Available Sources of Funds for the C19RM Mechanism
15th AFC Meeting	
GF/AFC15/EDP01	Confirmation of Target for Key Performance Indicator 7a – Allocation Utilization
GF/AFC15/EDP02	Approval of Available Sources of Funds for the C19RM Mechanism

14th Audit and Finance Committee Meeting Decision Points

GF/AFC14/EDP03: Amendments to Provident Fund Constitutional Declaration and Benefits Rules

1. Under the authority delegated by the Board pursuant to decision point GF/B20/DP18 (November 2009), the Audit and Finance Committee (“AFC”) has reviewed and discussed amendments affecting the benefits provided by the Provident Fund of the Global Fund to Fight AIDS, Tuberculosis and Malaria (“Provident Fund”).

2. Accordingly, the Audit and Finance Committee approves amendments to the Provident Fund Constitutional Declaration and Benefits Rules, as set forth in Annex 1 to GF/AFC14/ERO3.

Budgetary implications (included in, or additional to, OPEX budget)

The estimated cost to the Global Fund Provident Fund budget arising from the amendment to the Constitutional Declaration and Benefit Rules, and the benefits provided thereunder is CHF1,400,768. This estimate is CHF 369,157 less than the actual cost to the Global Fund Provident Fund budget for the relevant benefits for 2020. For further details on costs, please see the table summary on page 12. There is no additional cost to the OPEX budget.

GF/AFC14/EDP04: Approval of Available Sources of Funds for the C19RM Mechanism

1. The Audit and Finance Committee recognizes the Board decision points:
 - a. GF/B42/EDP11 (April 2020), creating a temporary COVID-19 response mechanism (C19RM) and approving the mobilization of additional resources from private and public donors for C19RM; and
 - b. GF/B43/EDP12 (September 2020), extending the period to approve C19RM requests through 15 April 2021 and requesting the Secretariat to return to the Board should total additional funding for C19RM exceed US\$ 500 million.
2. Based on its review and discussion of the Secretariat’s analysis of sources and uses of funds, as presented in GF/AFC14/ERO4, the Audit and Finance Committee:
 - a. approves the additional amount of US\$ 41 million as available sources of funds;
 - b. acknowledges that the additional amount of US\$ 41 million will be applied to C19RM pursuant to Board decision points GF/B42/EDP11 and GF/B43/EDP12; and

- c. accepts that the total available sources of funds for C19RM shall accordingly be US\$ 759 million.

Budgetary implications (included in, or additional to, OpEx budget): n/a

15th Audit and Finance Committee Meeting Decision Points

GF/AFC15/EDP01: Confirmation of Target for Key Performance Indicator 7a – Allocation Utilization

1. Based on its review and discussion of the proposal presented by the Secretariat, the Audit and Finance Committee (the “AFC”) recommends that the Board approve the performance target for Key Performance Indicator 7a as set forth in GF/AFC15/ER01.
2. Accordingly, the AFC recommends the following decision point to the Board for approval at its 45th Meeting in May 2021:

GF/B45/EDP01: Key Performance Indicator 7a: Allocation Utilization

Based on the recommendation of the Audit and Finance Committee, the Board approves the performance target for Key Performance Indicator 7a as presented in GF/B45/ER01.

This decision has no budgetary implications.

GF/AFC15/EDP02: Approval of Available Sources of Funds for the C19RM Mechanism

1. The Audit and Finance Committee recognizes the Board decision points:
 - a. GF/B42/EDP11 (April 2020), creating a temporary COVID-19 response mechanism (C19RM) and approving the mobilization of additional resources from private and public donors for C19RM;
 - b. GF/B43/EDP12 (September 2020), extending the period to approve C19RM requests through 15 April 2021 and requesting the Secretariat to return to the Board should total additional funding for C19RM exceed US\$ 500 million; and
 - c. GF/B44/EDP18 (March 2021), extending the period to mobilize additional funds, which will be used to support C19RM, through 31 December 2021 and to award C19RM funds through 31 March 2022, on the terms set forth in such decision point.
2. Based on its review and discussion of the Secretariat’s analysis of sources and uses of funds, as presented in GF/AFC15/ER02, the Audit and Finance Committee:
 - a. approves the additional amount of US\$ 3,619 million as available sources of funds;
 - b. acknowledges that the additional amount of US\$ 3,619 million will be applied to C19RM pursuant to Board decision points GF/B42/EDP11, GF/B43/EDP12 and GF/B44/EDP18; and
 - c. accepts that the total available sources of funds for C19RM shall accordingly be US\$ 4,378 million.

Budgetary implications (included in, or additional to, OpEx budget): A portion of the additional funds approved by this decision, not exceeding 3%, will fund incremental management and operating costs directly attributable to the second extension of C19RM.